HER-1 vaccine(Center of Molecular Immunology)(HER-1 vaccine(Center of Molecular Immunology)) - 药物靶点：EGFR_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

通用抗原疫苗、治疗性疫苗

别名

HER-1 vaccine、HER-1-ECD-VSSP、HER1-VSSP vaccine

+ [2]

靶点

EGFR

作用机制

EGFR调节剂(表皮生长因子受体erbB1调节剂)、免疫刺激剂

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症

前列腺癌

原研机构

Center For Molecular Immunology

在研机构

Center For Molecular Immunology

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 HER-1 vaccine(Center of Molecular Immunology) 相关的临床试验

RPCEC00000258 / Suspended临床1期

Phase I study with the HER1 / VSSP therapeutic vaccine in patients with hormone-castration-resistant prostate cancer, advanced squamous cell carcinoma of the head and neck and colon cancer

开始日期2017-11-15

申办/合作机构

Center For Molecular Immunology

RPCEC00000219 / Completed临床1期

Phase I clinical trial of the HER-1 vaccine in patients with prostate tumors of epithelial origin. - EC FI HER-1 CPRC

开始日期2009-10-23

申办/合作机构

Center For Molecular Immunology

100 项与 HER-1 vaccine(Center of Molecular Immunology) 相关的临床结果

登录后查看更多信息

100 项与 HER-1 vaccine(Center of Molecular Immunology) 相关的转化医学

登录后查看更多信息

100 项与 HER-1 vaccine(Center of Molecular Immunology) 相关的专利（医药）

登录后查看更多信息

6

项与 HER-1 vaccine(Center of Molecular Immunology) 相关的文献（医药）

2021-05-04·Immunopharmacology and Immunotoxicology4区 · 医学

Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study

4区 · 医学

Article

作者: León Goñi, Avelina ; Fuentes Morales, Dasha ; Hernández Fernández, Diana Rosa ; Sánchez Ramírez, Belinda ; Pérez Barreda, Aylen ; Acosta Lago, Eric ; Blanco Gámez, Diuris ; Casacó Parada, Ángel ; Bergado Báez, Gretchen ; Mancebo Rodríguez, Axel

Purpose: A vaccine composition based on the extracellular domain of the human epidermal growth factor receptor 1 (HER1-ECD) and the combination of VSSP (very small size proteoliposomes) and Montanide ISA 51 adjuvants when used by intramuscular route, demonstrated promising results in preclinical studies. However, in order to avoid potential adverse events due to the use of Montanide, it is proposed to modify the vaccine formulation by using VSSP (very small size proteoliposomes) adjuvant alone, and to evaluate the quality of subcutaneously induced immune response. This study aimed to assess the immunotoxicological effects of HER1 vaccine in Cercopithecus aethiops.Materials and methods: Fifteen monkeys were randomized into four groups: Negative Control (Tris/NaCl, s.c.), Positive Control (200 µg HER1-ECD/VSSP/Montanide ISA-51 VG, i.m), Low Dose (200 µg HER1-ECD/VSSP/Tris NaCl, s.c.) and High Dose (800 µg HER1-ECD/VSSP/Tris NaCl, s.c). All monkeys received 7 doses and were daily inspected for clinical signs. Body weight, rectal temperature, cardiac and respiratory rates were measured during the study, and electrocardiographical and ophthalmological studies were performed. Humoral and cellular immune response and clinical pathology parameters were analyzed.Results: Animal's survival in the study was 100% (n = 15). Administration site reactions were observed in the Positive Control animals (n = 4). HER1 vaccine administered subcutaneously (High Dose Group) achieved good IgG antibody titers although lower than the Positive Control group, but with higher ability to inhibit HER1 phosphorylation. Conclusions: This suggests that the alternative of eliminating the use of Montanide in the HER1 vaccine preparation and the using subcutaneous route is feasible.

2018-01-01·Seminars in Oncology3区 · 医学

HER1-based vaccine: Simultaneous activation of humoral and cellular immune response

3区 · 医学

Review

作者: Mazorra Herrera, Zaima ; Bergado Báez, Gretchen ; Hernández Fernández, Diana R ; Sánchez Ramírez, Belinda

The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines as safe therapeutic alternatives for the treatment of cancer.

2011-01-01·The Journal of Immunology2区 · 医学

Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant

2区 · 医学

Article

作者: Fernández, Audry ; Bronte, Vincenzo ; Clavell, Marilyn ; Fernández, Luis E. ; Marigo, Ilaria ; Dolcetti, Luigi ; Mesa, Circe ; Oliver, Liliana

AbstractThe interaction between cancer vaccine adjuvants and myeloid-derived suppressor cells (MDSCs) is currently poorly understood. Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in patients with renal carcinoma, breast cancer, prostate cancer, and cervical intraepithelial neoplasia grade III. We found that VSSP adjuvant induced a significant splenomegaly due to accumulation of CD11b+Gr-1+ cells. However, VSSP-derived MDSCs showed a reduced capacity to suppress both allogeneic and Ag-specific CTL response compared with that of tumor-induced MDSCs. Moreover, splenic MDSCs isolated from tumor-bearing mice treated with VSSP were phenotypically more similar to those isolated from VSSP-treated tumor-free mice and much less suppressive than tumor-induced MDSCs, both in vitro and in vivo. Furthermore, different from dendritic cell vaccination, inoculation of VSSP-based vaccine in EG.7-OVA tumor-bearing mice was sufficient to avoid tumor-induced tolerance and stimulate an immune response against OVA Ag, similar to that observed in tumor-free mice. This effect correlated with an accelerated differentiation of MDSCs into mature APCs that was promoted by VSSP. VSSP used as a cancer vaccine adjuvant might thus improve antitumor efficacy not only by stimulating a potent immune response against tumor Ags but also by reducing tumor-induced immunosuppression.

100 项与 HER-1 vaccine(Center of Molecular Immunology) 相关的药物交易

登录后查看更多信息